Biotech, Life Science & Health Care Industries

Introduction: Nicholas Piramal India Limited is one of India's largest companies with an unmatched record of managing JVs/Alliances/Partnerships, and a proven commitment to IPR. With strong brand management and

...

sales capabilities, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class, accredited Clinical Research Organisation, NPIL is poised to emerge as India's pharma powerhouse. With growth fuelled through a strategy of partnerships, quality acquisitions, brand building, focused selling and manufacturing, NPIL's consolidated net sales turnover was US$ 313 million (INR 14.1 billion) in 2005-06 (April to March)".

NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organic growth fuelled through a strategy of acquisitions, brand building and focused selling, and manufacturing. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, including the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.

The company was formed when the Piramal Group acquired Nicholas Laboratories, a small formulations company in 1988 from Sara Lee. It has followed a multi-pronged strategy to integrate and maximize synergies with the planned acquisitions and develop and consolidate its major strength in marketing to therapeutic niches.

Managed by a team of highly proficient industry professionals, NPIL's key strengths come from its strong brand building, selling and distribution, manufacturing and alliance/partnership management skills. The last, especially, are quite unique in the Indian context - few Indian Pharmaceutical have exhibited such a strong and consistent record in successfully and ethically managing JVs/Alliances and Partnerships as NPIL has.

Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widely respected and commended by its partners.

NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million) Piramal Enterprises (PEL), one of India's largest diversified business houses.

Area of Research: Nicholas Piramal India Limited (NPIL) has a deep commitment to healthcare, with a mission to “make a difference to the quality of life by reducing the burden of disease through R&D.” In order to realize its mission, NPIL has embarked upon on an ambitious program to discover and develop new chemical entities (NCE's) and Novel Drug Delivery Systems (NDDS) for the global market in select therapeutic areas including Cancer, Inflammation, Diabetes/Metabolic Disorders, and Infectious Diseases.

Products: NPIL is a diversified pharma major keen to position itself as partner of choice for global drug companies providing cost effective solutions as a healthcare provider across the board. With this mission in mind, it has invested in state of the art facilities in high growth areas like path labs, specialty chemicals, clinical evaluation of new drugs, in addition to formulations and drug manufacture.

NPIL has the following areas of business expertise:

Bulk drug manufacture for domestic and export markets

Specialty labs and chemicals

Formulation development

Genomic information provider

Herbal products

Technology: The R&D effort is anchored out of NPIL’s brand-new research centre, the Nicholas Piramal Research Centre in Goregaon, Mumbai. This is a state-of-the-art, 300,000 square-foot R&D facility, which will be the largest pharmaceutical research centre under one roof in India. It houses laboratories for natural products, herbal products, medicinal - synthetic chemistry, cheminformatics, cell-based screening assays, animal pharmacology and molecular biology, process and scale-up chemistry and pharmaceutical R&D (formulations based on conventional and novel drug delivery systems).

The multicentric activities are spearheaded by Dr. Somesh Sharma, the Chief Scientific Officer (CSO) of the company. All the functions undertake independent as well as collaborative research projects in their respective areas of expertise, and are guided by internal core teams with inputs from external consultants – both national and international.

Ammenities: Nicholas Piramal Research Centre (NPRC)

Inaugurated on November 18, 2004, by the President of India, His Excellency Dr. A. P. J. Abdul Kalam, NPRC is of the same caliber as the R&D facilities found at top, multi-national pharma companies. The Research Centre embodies a vision to establish a world-class R&D program that would provide opportunities for young scientists in India to work in a world-class R&D environment. The labs are equipped with the best instrumentation and state-of-the-art technology in the world. The interior of the building embodies unique architecture with large open spaces interspersed with many pieces of the finest in art, creating a workplace that it as much fun to be in as it is to work in. The unique environment will foster teamwork, cross-functional interactions and innovation.

Press Release:

Piramal Life Sciences Makes Oral Presentation on "Breakthrough Molecule for Type II Diabetes at ADA Convention"

Piramal Life Sciences Limited now a listed company

Piramal Life Sciences Initiates Phase I Trials with a New Molecule for Type II Diabetes in Europe

Piramal Diagnostics introduces Asia's first high-definition PET/CT Scanner

Stock: http://www.moneycontrol.com/financials/piramalhealthcare/balance-sheet/PH05

Source: http://www.nicholaspiramal.com